.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,414,921

« Back to Dashboard
Patent 8,414,921 protects JANUMET and is included in one NDA. There has been one Paragraph IV challenge on Janumet. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has nine patent family members in six countries.

Summary for Patent: 8,414,921

Title:Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Abstract: Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
Inventor(s): Kamali; Ashkan (West Conshohocken, PA), Alani; Laman (Lansdale, PA), Fliszar; Kyle A. (Quakertown, PA), Ghosh; Soumojeet (Lansdale, PA), Tijerina; Monica (Doylestown, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/085,722
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 0th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp Dohme
JANUMET
metformin hydrochloride; sitagliptin phosphate
TABLET;ORAL022044-002Mar 30, 2007RXYes8,414,921► subscribeY METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
Merck Sharp Dohme
JANUMET
metformin hydrochloride; sitagliptin phosphate
TABLET;ORAL022044-001Mar 30, 2007RXNo8,414,921► subscribeY METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,414,921

PCT Information
PCT FiledDecember 12, 2006PCT Application Number:PCT/US2006/047380
PCT Publication Date:July 12, 2007PCT Publication Number: WO2007/078726

International Patent Family for Patent: 8,414,921

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2006333151► subscribe
Canada2633167► subscribe
China101365432► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc